source
- FDA rejects Capricor's Duchenne cell therapy citing serious data integrity violationsThe Food and Drug Administration issued a second rejection of Capricor Therapeutics' cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy. The agency said the revised application…
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.